Realta Life Sciences has raised an additional $40 million in the final tranche of its Series A financing, bringing total funding to more than $150 million for its hypoxic ischemic encephalopathy treatment. The company framed the round as part of ongoing development progress under a mission-driven, family-office investor model. The incremental capital comes as neonatal and early-life neuroprotective programs continue to attract attention, especially where mechanisms target acute injury pathways. Realta’s updated financing position also supports manufacturing and clinical execution steps needed for later-stage development. For biopharma leaders, the deal adds another example of continued capital formation in high-need neurocritical care indications where regulatory pathways can be steep.